LindaRDuskaMD

Obstetrics & Gynecology • Charlottesville, VA

Gynecologic Oncology, Hospice & Palliative Medicine

Professor of Obstetrics & Gynecology, University VA School of Medicine

Join to view full profile

Dr. Duska is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Duska's full profile

Already have an account?

Office
1240 Lee St
Charlottesville, VA 22908
Phone+1 434-924-5100

Fax+1 434-982-1840
Is this information wrong?

Education & Training

Massachusetts General HospitalFellowship, Gynecologic Oncology, 1995 - 1998
Johns Hopkins UniversityResidency, Obstetrics and Gynecology, 1991 - 1995
New York University School of MedicineClass of 1991

Certifications & Licensure

VA State Medical License 2008 - 2024
FL State Medical License 2019 - 2021
MA State Medical License 1995 - 2012
American Board of Internal Medicine Hospice and Palliative Medicine
American Board of Obstetrics and Gynecology Obstetrics & Gynecology
American Board of Obstetrics and Gynecology Gynecologic Oncology

Awards, Honors, & Recognition

America's Top Doctors Castle Connolly, 2012-2014
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
America's Top Doctors for Cancer Castle Connolly, 2011-2013
Fellow (FACS) American College of Surgeons
Fellow (FACOG) American Congress of Obstetricians and Gynecologists
Join now to see all

Clinical Trials

Cetuximab, Cisplatin, and Radiotherapy in Women With Locally Advanced Cervical Carcinoma Start of enrollment: 2006 Feb 01
Unknown status
Phase 2
Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer Start of enrollment: 2009 Oct 28
Completed
Phase 1
Intraperitoneal Bortezomib and Carboplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Start of enrollment: 2010 Apr 05
Completed
Phase 1
Ixabepilone in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus Previously Treated With Chemotherapy Start of enrollment: 2010 Nov 01
Completed
Phase 2
A Prospective Trial of COXEN Chemotherapy Prediction Start of enrollment: 2010 Oct 01
Withdrawn
Not Applicable
Bristol-Myers Squibb Dasatinib Src Inhibition in Endometrial Cancer Start of enrollment: 2012 Jan 01
Completed
Early Phase 1
A Randomized Study of Safety and Efficacy of Pazopanib and Gemcitabine in Persistent or Relapsed Ovarian Cancer Start of enrollment: 2012 Sep 01
Completed
Phase 2
Zoptarelin Doxorubicin (AEZS 108) as Second Line Therapy for Endometrial Cancer Start of enrollment: 2013 Apr 01
Completed
Phase 3
Medroxyprogesterone Acetate With or Without Entinostat Before Surgery in Treating Patients With Endometrioid Endometrial Cancer Start of enrollment: 2017 Oct 11
Completed
Early Phase 1
Bevacizumab and Anetumab Ravtansine or Paclitaxel in Treating Patients With Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Start of enrollment: 2018 Oct 12
Active, not recruiting
Phase 2
A Study of Weekly Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With Safety Run-in (innovaTV 208) Start of enrollment: 2019 Mar 20
Completed
Phase 2
Treatment Effects on Development of Chemotherapy-Induced Peripheral Neuropathy in Patients With Cancer Start of enrollment: 2019 May 14
Active, not recruiting
Tisotumab Vedotin vs Chemotherapy in Recurrent or Metastatic Cervical Cancer Start of enrollment: 2021 Feb 22
Recruiting
Phase 3
Join now to see all

Publications & Presentations

PubMed

Cost effectiveness of pembrolizumab plus lenvatinib compared with chemotherapy for treating previously treated advanced endometrial cancer in Sweden.
Lewis Ralph, Kate Young, Navneet Upadhyay, Vimalanand Shrikant Prabhu, Christina Ljungcrantz, Rachid Massaad, Ruifeng Xu, Anna Giertz, Adil Merchant, Robert Orlowski, ...> ;Journal of Medical Economics. 2024 Mar 26
Presence of low volume metastases does not alter management in node-negative, early-stage cervical cancer patients who underwent postoperative adjuvant therapy: A retr...
Crawford, M., O'Brien, R., Welp, A., Sullivan, S., Duska, L.> ;Gynecologic Oncology Reports. 2024 Feb 1
Large bowel recurrence of endometrial adenocarcinoma years after treatment: A single-institution case series and review of the literature.
Welp, A., Duska, L.> ;Gynecologic Oncology Reports. 2024 Feb 1
How far is too far? Cancer prevention and clinical trial enrollment in geographically underserved patient populations.
Ring, K., Duska, L.> ;Gynecologic Oncology. 2024 Jan 24
3 citations
Top advances of the year: Cervical cancer.
Sarah E Podwika, Linda R Duska> ;Cancer. 2023 Mar 1
Evaluating the risk of post-operative abscess formation following use of hemostatic agents at time of hysterectomy.
Megan Howard, Jeanine N Staples, Samhita Nelamangala, Connell Kling, Linda R Duska> ;Gynecologic Oncology Reports. 2022 Dec 1
3 citations
Treatment patterns and real-world clinical outcomes in patients with advanced endometrial cancer who are microsatellite instability (MSI)-high or are mismatch repair d...
Sneha S Kelkar, Vimalanand S Prabhu, Shelby Corman, Shardul Odak, Nifasha Rusibamayila, Cynthia Macahilig, Robert Orlowski, Linda Duska> ;Gynecologic Oncology. 2023 Feb 1
1 citations
Overcoming disparities to improve cancer care: The story of cervical cancer.
Linda R Duska> ;Cancer. 2022 Dec 1
4 citations
Treatment patterns and real-world clinical outcomes in patients with advanced endometrial cancer that are non-microsatellite instability high (non-MSI-high) or mismatc...
Sneha S Kelkar, Vimalanand S Prabhu, Jingchuan Zhang, Shelby Corman, Cynthia Macahilig, Nifasha Rusibamayila, Shardul Odak, Linda R Duska> ;Gynecologic Oncology Reports. 2022 Aug 1
2 citations
A phase II trial of bevacizumab and rucaparib in recurrent carcinoma of the cervix or endometrium.
C G Jackson, K N Moore, L Cantrell, B K Erickson, L R Duska, D L Richardson, L M Landrum, L L Holman, J L Walker, R S Mannel, K M Moxley, L Queimado, A Cohoon, K Ding,...> ;Gynecologic Oncology. 2022 Jul 1
22 citations
Translational randomized phase II trial of cabozantinib in combination with nivolumab in advanced, recurrent, or metastatic endometrial cancer.
Stephanie Lheureux, Daniela E Matei, Panagiotis A Konstantinopoulos, Ben X Wang, Ramy Gadalla, Matthew S Block, Andrea Jewell, Stephanie L Gaillard, Michael McHale, Ca...> ;Journal for Immunotherapy of Cancer. 2022 Mar 1
113 citations
Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) or profi...
Ana Oaknin, Lucy Gilbert, Anna V Tinker, Jubilee Brown, Cara Mathews, Joshua Press, Renaud Sabatier, David M O'Malley, Vanessa Samouelian, Valentina Boni, Linda Duska,...> ;Journal for Immunotherapy of Cancer. 2022 Jan 1
7 citations
A Surgical Window Trial Evaluating Medroxyprogesterone Acetate with or without Entinostat in Patients with Endometrial Cancer and Validation of Biomarkers of Cellular ...
Linda R. Duska, Virginia L. Filiaci, Joan L. Walker, Laura L. Holman, Emily K. Hill, Richard G. Moore, Kari L. Ring, Michael L. Pearl, Carolyn Y. Muller, Christina L. ...> ;Clinical Cancer Research. 2021 May 15
4 citations
Post hoc analyses of GOG 9923: Does BRCA status affect toxicities?: An NRG oncology study.
J. Gillen, Austin Miller, Katherine M. Bell-McGuinn, Russell J. Schilder, Joan L. Walker, Cara Mathews, Linda R. Duska, Saketh R. Guntupalli, Roisin E. O'Cearbhaill, J...> ;Gynecologic Oncology. 2021 May 1
2 citations
Society of Gynecologic Oncology recommendations for fellowship education during the COVID-19 pandemic and beyond: Innovating programs to optimize trainee success.
J. Stuart Ferriss, Steve Rose, Bunja Rungruang, Renata R. Urban, Ryan J. Spencer, Shitanshu Uppal, Abdulrahman K. Sinno, Linda R. Duska, Christine Walsh> ;Gynecologic Oncology. 2021 Jan 1
10 citations
A phase Ib/II and pharmacokinetic study of EP0057 (formerly CRLX101) in combination with weekly paclitaxel in patients with recurrent or persistent epithelial ovarian,...
Linda R. Duska, Carolyn N. Krasner, David M. O'Malley, John L. Hays, Susan C. Modesitt, Cara Mathews, Kathleen N. Moore, Premal H. Thaker, Anthony B. Miller, Christoph...> ;Gynecologic Oncology. 2021 Mar 1
30 citations
Results of an early safety analysis of a study of the combination of pembrolizumab and pelvic chemoradiation in locally advanced cervical cancer.
Linda R. Duska, Jennifer Scalici, Sarah M. Temkin, Julie K. Schwarz, Erin K. Crane, Katherine M. Moxley, Chad A. Hamilton, Stephanie L. Wethington, Gina R. Petroni, Ni...> ;Cancer. 2020 Nov 15
109 citations
Berzosertib plus gemcitabine versus gemcitabine alone in platinum-resistant high-grade serous ovarian cancer: a multicentre, open-label, randomised, phase 2 trial.
Panagiotis A. Konstantinopoulos, Su Chun Cheng, Andrea E. Wahner Hendrickson, Richard T. Penson, Susan Schumer, L. Austin Doyle, Elizabeth K. Lee, Elise C. Kohn, Linda...> ;The Lancet. Oncology. 2020 Jun 15
15 citations
Loss of MHC Class I Expression in HPV-associated Cervical and Vulvar Neoplasia: A Potential Mechanism of Resistance to Checkpoint Inhibition.
Megan E Dibbern, Timothy N. J. Bullock, Taylor M Jenkins, Linda R. Duska, Mark H. Stoler, Anne M. Mills> ;The American Journal of Surgical Pathology. 2020 Sep 1
7 citations
A randomized phase II evaluation of weekly gemcitabine plus pazopanib versus weekly gemcitabine alone in the treatment of persistent or recurrent epithelial ovarian, f...
Linda R. Duska, Gina R. Petroni, Nikole Varhegyi, Jubilee Brown, Danijela Jelovac, Kathleen N. Moore, William P. McGuire, Christopher J. Darus, Lisa Barroilhet, Angele...> ;Gynecologic Oncology. 2020 Jun 1
22 citations
Are ethnic and racial minority women less likely to participate in clinical trials
Shweta N. Patel, Jeanine N. Staples, Christine Garcia, J. Stuart Ferriss, Linda R. Duska> ;Gynecologic Oncology. 2020 May 1
1 citations
Stuck in the middle: diagnostic and clinical management challenges surrounding CIN2
Anne M. Mills, Linda R. Duska> ;BJOG. 2020 May 1
11 citations
Validation of the surprise question in gynecologic oncology: A one-question screen to promote palliative care integration and advance care planning.
Lisa A. Rauh, Mackenzie W. Sullivan, Fabian Camacho, Monica J. Janke, Linda R. Duska, Chelsea Chandler, Paniti Sukumvanich, Madeleine Courtney-Brooks, Carolyn Lefkowits> ;Gynecologic Oncology. 2020 Mar 12
21 citations
Looking past PD-L1: expression of immune checkpoint TIM-3 and its ligand galectin-9 in cervical and vulvar squamous neoplasia.
Jacob Curley, Mark R. Conaway, Zachary Chinn, Linda R. Duska, Mark H. Stoler, Anne M. Mills> ;Modern Pathology. 2020 Mar 6
5 citations
Chemotherapy alone may have equivalent survival as compared to suboptimal surgery in advanced endometrial cancer patients.
Lisa A. Rauh, Jeanine N. Staples, Linda R. Duska> ;Gynecologic Oncology Reports. 2020 Jan 17
Join now to see all

Lectures

Surgery Is Critical to a Multidisciplinary Approach to Ovarian Cancer
ASCO Annual Meeting 2019 - Chicago, IL - 6/2/2019

Press Mentions

What’s the Endometrial Cancer Risk Factor Behind a Rise in Cases? The Answer Might Surprise YouAugust 30th, 2022
HPV Vaccine for Adults: What to Know About This Cancer-Preventing VaccineMarch 10th, 2022
Myths vs. Facts: HPV Vaccine Side Effects, Risks, & Virginia’s New LawJuly 27th, 2021
Join now to see all